April 30, 2010 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) announced presentation of additional results from a recently completed Phase I clinical trial of its immunotherapeutic peptide AE37 in prostate cancer patients.

AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications. The presentation was made at the 25th Anniversary Congress of the European Association of Urology in Barcelona, Spain from April 16 through April 20.

In addition to safety and the demonstration of a specific immunological response to AE37, it was shown that circulating levels of the extracellular domain of the HER2 protein were decreased in immunized patients compared to pre-vaccine levels. The AE37 vaccine was designed using a fragment of the HER2 protein and proprietary modifications developed at Antigen Express. The immunity generated by AE37 appeared to be long lasting, as significant vaccine-specific delayed type hypersensitivity reactions were still apparent 6 months after the end of vaccinations. These results add to the body of data previously generated showing that AE37 is safe and immunologically active. Interim results from an ongoing Phase II trial of AE37 in breast cancer patients indicated that there were fewer recurrences in patients receiving AE37.

The EAU represents the leading authority within Europe on urological practice, research and education. Over 13,000 medical professionals have joined its ranks and help to create forward-looking solutions for continuous improvement, professional growth, and knowledge sharing.

The EAU delivers training, stimulates research, and broadcasts information. The EAU's scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.

Streaming Research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

 [frlylrf] [biomedphrm] [bsnnssb] [dvcmntnmc]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.